LIGAND PHARMACEUTICALS INC's ticker is LGND and the CUSIP is 53220K504. A total of 181 filers reported holding LIGAND PHARMACEUTICALS INC in Q4 2014. The put-call ratio across all filers is 1.98 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $239,000 | -12.8% | 2,400 | 0.0% | 0.33% | -8.2% |
| Q2 2019 | $274,000 | -9.3% | 2,400 | 0.0% | 0.36% | -9.7% |
| Q1 2019 | $302,000 | -40.6% | 2,400 | -52.0% | 0.40% | +24.0% |
| Q4 2016 | $508,000 | -28.9% | 5,000 | -28.6% | 0.32% | -29.3% |
| Q3 2016 | $714,000 | -0.3% | 7,000 | +16.7% | 0.46% | -4.6% |
| Q2 2016 | $716,000 | -4.5% | 6,000 | -14.3% | 0.48% | -7.3% |
| Q1 2016 | $750,000 | +38.4% | 7,000 | +40.0% | 0.52% | +42.1% |
| Q4 2015 | $542,000 | +26.6% | 5,000 | 0.0% | 0.37% | +19.6% |
| Q3 2015 | $428,000 | -47.0% | 5,000 | -37.5% | 0.31% | -41.6% |
| Q2 2015 | $807,000 | -4.8% | 8,000 | -27.3% | 0.52% | +40.9% |
| Q1 2015 | $848,000 | -11.5% | 11,000 | -38.9% | 0.37% | -12.9% |
| Q4 2014 | $958,000 | +13.2% | 18,000 | 0.0% | 0.43% | +8.9% |
| Q3 2014 | $846,000 | -9.4% | 18,000 | +20.0% | 0.39% | -8.6% |
| Q2 2014 | $934,000 | – | 15,000 | – | 0.43% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knott David M Jr | 115,000 | $7,682 | 2.90% |
| VILLERE ST DENIS J & CO LLC | 483,347 | $32,287 | 2.52% |
| Monarch Partners Asset Management LLC | 62,327 | $4,163,444 | 1.23% |
| Chicago Capital, LLC | 319,054 | $21,312,820 | 1.18% |
| RICE HALL JAMES & ASSOCIATES, LLC | 285,634 | $19,080,351 | 1.09% |
| Stephens Investment Management Group LLC | 454,416 | $30,713,977 | 0.56% |
| Smith, Graham & Co., Investment Advisors, LP | 65,372 | $4,366,850 | 0.53% |
| WOODSTOCK CORP | 55,014 | $3,674,935 | 0.49% |
| Court Place Advisors, LLC | 15,533 | $1,037,605 | 0.38% |
| ISTHMUS PARTNERS, LLC | 19,830 | $1,324,644 | 0.20% |